Amber Bio

About

Amber Bio is a biotechnology company based in Cambridge, Massachusetts, specializing in innovative gene editing technologies. The company is focused on developing therapies that can address genetic conditions previously deemed undruggable, utilizing multi-kilobase RNA writing technology. Founded by leaders in the CRISPR field, Amber Bio aims to create gene therapies that are safe, precise, and affordable, with the potential to treat a wide range of mutations with a single product. The company's proprietary platform combines RNA editing with AI models to enhance the treatment of diverse genetic disorders. This technology allows for larger edits than traditional methods, enabling the development of a unique RNA writing platform capable of addressing thousands of mutations across patients. Currently in the pre-clinical stage, Amber Bio is advancing its RNA-based gene editing platform and has secured significant investment to support its innovative genetic medicine programs.